Datasets:
question_id int64 | topic string | question string | options list | answer_index int64 | answer string | difficulty string | evidence_level string | citation string | golden_docs list | sources list |
|---|---|---|---|---|---|---|---|---|---|---|
1 | prognosis | Which of the following cancers has the WORST 5-year survival? | [
"Leukemia (AML, elderly)",
"Pancreatic",
"Liver (HCC)",
"Lung (SCLC)"
] | 3 | Lung (SCLC) | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/leuks.html | [
"cancer.md"
] | [
"cancer.md"
] |
2 | prognosis | Which of the following cancers has the WORST 5-year survival? | [
"Leukemia (AML, elderly)",
"Pancreatic",
"Lung (SCLC)",
"Liver (HCC)"
] | 2 | Lung (SCLC) | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/leuks.html | [
"cancer.md"
] | [
"cancer.md"
] |
3 | prognosis | Which of the following cancers has the WORST 5-year survival? | [
"Leukemia (AML, elderly)",
"Liver (HCC)",
"Pancreatic",
"Lung (SCLC)"
] | 3 | Lung (SCLC) | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/leuks.html | [
"cancer.md"
] | [
"cancer.md"
] |
4 | prognosis | Which of the following cancers has the WORST 5-year survival? | [
"Pancreatic",
"Lung (SCLC)",
"Leukemia (AML, elderly)",
"Liver (HCC)"
] | 1 | Lung (SCLC) | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/pancreas.html | [
"cancer.md"
] | [
"cancer.md"
] |
5 | prognosis | Which of the following cancers has the WORST 5-year survival? | [
"Lung (SCLC)",
"Leukemia (AML, elderly)",
"Lung (NSCLC)",
"Pancreatic"
] | 0 | Lung (SCLC) | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/lungb.html | [
"cancer.md"
] | [
"cancer.md"
] |
6 | biomarkers | Which biomarker corresponds to the HGNC gene symbol ERBB2? | [
"KRAS",
"HER2",
"BRAF V600E",
"EGFR"
] | 1 | HER2 | medium | Phase III RCT | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/her2-ref.md"
] | [
"know/her2-ref.md"
] |
7 | biomarkers | Which biomarker corresponds to the HGNC gene symbol EGFR? | [
"EGFR",
"KRAS",
"HER2",
"BRAF V600E"
] | 0 | EGFR | medium | Phase III RCT | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/her2-ref.md"
] | [
"know/her2-ref.md"
] |
8 | biomarkers | Which biomarker corresponds to the HGNC gene symbol KRAS? | [
"EGFR",
"KRAS",
"BRAF V600E",
"HER2"
] | 1 | KRAS | medium | Phase III RCT | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/her2-ref.md"
] | [
"know/her2-ref.md"
] |
9 | biomarkers | Which biomarker corresponds to the HGNC gene symbol BRAF? | [
"HER2",
"EGFR",
"BRAF V600E",
"KRAS"
] | 2 | BRAF V600E | medium | Phase III RCT | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/her2-ref.md"
] | [
"know/her2-ref.md"
] |
10 | prognosis | Which of the following cancers has the BEST 5-year survival? | [
"Pancreatic",
"Lung (SCLC)",
"Breast",
"Leukemia (AML, elderly)"
] | 2 | Breast | hard | Source-linked (SEER/ICD-10) | https://seer.cancer.gov/statfacts/html/pancreas.html | [
"cancer.md"
] | [
"cancer.md"
] |
11 | staging | A prostate biopsy showing Gleason score 3+3 corresponds to which Grade Group? | [
"Grade Group 1",
"Grade Group 5",
"Grade Group 4",
"Grade Group 3",
"Grade Group 2"
] | 0 | Grade Group 1 | hard | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"sites/prostate.md",
"know/prostate-ref.md"
] | [
"sites/prostate.md",
"know/prostate-ref.md"
] |
12 | staging | A prostate biopsy showing Gleason score 3+4 corresponds to which Grade Group? | [
"Grade Group 2",
"Grade Group 5",
"Grade Group 3",
"Grade Group 4",
"Grade Group 1"
] | 0 | Grade Group 2 | hard | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"sites/prostate.md",
"know/prostate-ref.md"
] | [
"sites/prostate.md",
"know/prostate-ref.md"
] |
13 | staging | A prostate biopsy showing Gleason score 4+3 corresponds to which Grade Group? | [
"Grade Group 3",
"Grade Group 5",
"Grade Group 4",
"Grade Group 1",
"Grade Group 2"
] | 0 | Grade Group 3 | hard | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"sites/prostate.md",
"know/prostate-ref.md"
] | [
"sites/prostate.md",
"know/prostate-ref.md"
] |
14 | staging | A prostate biopsy showing Gleason score 4+4 corresponds to which Grade Group? | [
"Grade Group 1",
"Grade Group 4",
"Grade Group 5",
"Grade Group 3",
"Grade Group 2"
] | 1 | Grade Group 4 | hard | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"sites/prostate.md",
"know/prostate-ref.md"
] | [
"sites/prostate.md",
"know/prostate-ref.md"
] |
15 | staging | A prostate biopsy showing Gleason score 4+5 corresponds to which Grade Group? | [
"Grade Group 3",
"Grade Group 5",
"Grade Group 1",
"Grade Group 4",
"Grade Group 2"
] | 1 | Grade Group 5 | hard | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"sites/prostate.md",
"know/prostate-ref.md"
] | [
"sites/prostate.md",
"know/prostate-ref.md"
] |
16 | staging | "Benign" is the WHO histologic grade defined as: | [
"Grade 3",
"Grade 1",
"Grade 4",
"Grade 2"
] | 1 | Grade 1 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15758009 | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] |
17 | staging | "Low-grade" is the WHO histologic grade defined as: | [
"Grade 1",
"Grade 2",
"Grade 3",
"Grade 4"
] | 1 | Grade 2 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15758009 | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] |
18 | staging | "Malignant" is the WHO histologic grade defined as: | [
"Grade 3",
"Grade 2",
"Grade 1",
"Grade 4"
] | 0 | Grade 3 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15758009 | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] |
19 | staging | "Highly malignant" is the WHO histologic grade defined as: | [
"Grade 2",
"Grade 4",
"Grade 3",
"Grade 1"
] | 1 | Grade 4 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15758009 | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] | [
"types/cns-cancers.md",
"know/cns-cancers-ref.md"
] |
20 | staging | In the BCLC system, which stage matches "1–2"? | [
"Stage B",
"Stage A",
"Stage D",
"Stage C"
] | 3 | Stage C | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/32402160 | [
"sites/liver.md",
"know/liver-ref.md"
] | [
"sites/liver.md",
"know/liver-ref.md"
] |
21 | staging | In the BCLC system, which stage matches "3–4"? | [
"Stage D",
"Stage A",
"Stage C",
"Stage B"
] | 0 | Stage D | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/32402160 | [
"sites/liver.md",
"know/liver-ref.md"
] | [
"sites/liver.md",
"know/liver-ref.md"
] |
22 | subtypes | Which breast cancer subtype is found in approximately ~70–80%? | [
"Invasive lobular carcinoma (ILC)",
"Invasive ductal carcinoma (IDC)",
"Ductal carcinoma in situ (DCIS)",
"Medullary carcinoma"
] | 1 | Invasive ductal carcinoma (IDC) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
23 | subtypes | Which breast cancer subtype is found in approximately ~5–15%? | [
"Ductal carcinoma in situ (DCIS)",
"Medullary carcinoma",
"Invasive ductal carcinoma (IDC)",
"Invasive lobular carcinoma (ILC)"
] | 3 | Invasive lobular carcinoma (ILC) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
24 | subtypes | Which breast cancer subtype is found in approximately ~15–20%? | [
"Ductal carcinoma in situ (DCIS)",
"Medullary carcinoma",
"Invasive ductal carcinoma (IDC)",
"Invasive lobular carcinoma (ILC)"
] | 0 | Ductal carcinoma in situ (DCIS) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
25 | subtypes | Which breast cancer subtype is found in approximately ~3%? | [
"Medullary carcinoma",
"Invasive ductal carcinoma (IDC)",
"Ductal carcinoma in situ (DCIS)",
"Invasive lobular carcinoma (ILC)"
] | 0 | Medullary carcinoma | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
26 | subtypes | Which breast cancer subtype is found in approximately ~2%? | [
"Invasive ductal carcinoma (IDC)",
"Invasive lobular carcinoma (ILC)",
"Ductal carcinoma in situ (DCIS)",
"Mucinous (colloid) carcinoma"
] | 3 | Mucinous (colloid) carcinoma | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
27 | subtypes | Which breast cancer subtype is found in approximately ~1%? | [
"Ductal carcinoma in situ (DCIS)",
"Invasive lobular carcinoma (ILC)",
"Invasive ductal carcinoma (IDC)",
"Paget disease of the nipple"
] | 3 | Paget disease of the nipple | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
28 | subtypes | Which breast cancer subtype is found in approximately ~10–15%? | [
"Invasive ductal carcinoma (IDC)",
"Triple-negative (TNBC)",
"Ductal carcinoma in situ (DCIS)",
"Invasive lobular carcinoma (ILC)"
] | 1 | Triple-negative (TNBC) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
29 | subtypes | Which breast cancer subtype is found in approximately ~1–5%? | [
"Invasive ductal carcinoma (IDC)",
"Inflammatory breast cancer",
"Ductal carcinoma in situ (DCIS)",
"Invasive lobular carcinoma (ILC)"
] | 1 | Inflammatory breast cancer | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
30 | subtypes | Which breast cancer subtype is found in approximately ~40%? | [
"Ductal carcinoma in situ (DCIS)",
"Invasive lobular carcinoma (ILC)",
"Luminal A",
"Invasive ductal carcinoma (IDC)"
] | 2 | Luminal A | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
31 | subtypes | Which breast cancer subtype is found in approximately ~20%? | [
"Invasive ductal carcinoma (IDC)",
"Invasive lobular carcinoma (ILC)",
"Luminal B",
"Ductal carcinoma in situ (DCIS)"
] | 2 | Luminal B | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"sites/breast.md",
"know/breast-ref.md"
] | [
"sites/breast.md",
"know/breast-ref.md"
] |
32 | drugs | Which drug is a mAb (IgG1)? | [
"T-DXd (Enhertu)",
"Trastuzumab (H)",
"Nab-paclitaxel",
"Ifosfamide"
] | 1 | Trastuzumab (H) | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
33 | drugs | Which drug is a ADC? | [
"Trastuzumab (H)",
"Cyclophosphamide",
"T-DM1",
"Nab-paclitaxel"
] | 2 | T-DM1 | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
34 | drugs | Which drug is a taxane? | [
"Pertuzumab (P)",
"Paclitaxel",
"Temozolomide",
"T-DXd (Enhertu)"
] | 1 | Paclitaxel | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
35 | drugs | Which drug is a alkylating agent? | [
"T-DM1",
"Nab-paclitaxel",
"Cyclophosphamide",
"Trastuzumab (H)"
] | 2 | Cyclophosphamide | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
36 | drugs | Which drug is a platinum agent? | [
"Pertuzumab (P)",
"Cisplatin",
"T-DM1",
"Paclitaxel"
] | 1 | Cisplatin | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
37 | drugs | Which drug is a aromatase inhibitor? | [
"T-DXd (Enhertu)",
"Paclitaxel",
"Pertuzumab (P)",
"Anastrozole"
] | 3 | Anastrozole | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
38 | drugs | Which drug is a CDK4/6 inhibitor? | [
"Abemaciclib",
"Nab-paclitaxel",
"Trastuzumab (H)",
"T-DM1"
] | 0 | Abemaciclib | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
39 | drugs | Which drug is a anti-PD-L1 mAb? | [
"Nab-paclitaxel",
"T-DM1",
"Pertuzumab (P)",
"Durvalumab"
] | 3 | Durvalumab | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
40 | drugs | Which drug is a anti-PD-1 mAb? | [
"Trastuzumab (H)",
"Paclitaxel",
"T-DXd (Enhertu)",
"Nivolumab"
] | 3 | Nivolumab | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
41 | drugs | Which drug is a KRAS G12C inhibitor? | [
"Sotorasib",
"Paclitaxel",
"Pertuzumab (P)",
"T-DM1"
] | 0 | Sotorasib | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
42 | drugs | Which drug is a fluoropyrimidine? | [
"Paclitaxel",
"Pertuzumab (P)",
"T-DXd (Enhertu)",
"Capecitabine"
] | 3 | Capecitabine | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
43 | drugs | Which drug is a multi-kinase TKI? | [
"Pertuzumab (P)",
"Sorafenib",
"T-DM1",
"Nab-paclitaxel"
] | 1 | Sorafenib | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
44 | drugs | Which drug is a corticosteroid? | [
"Prednisone",
"Paclitaxel",
"T-DM1",
"Pertuzumab (P)"
] | 0 | Prednisone | easy | KB-source | https://pubmed.ncbi.nlm.nih.gov/16236738 | [
"know/curated.md"
] | [
"know/curated.md",
"know/her2-ref.md"
] |
45 | codes | Which ICD-10 code is assigned to Breast cancer? | [
"C50",
"C22",
"C81–C96",
"C18–C21"
] | 0 | C50 | medium | ICD-10 (C50) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/breast.md",
"sites/liver.md",
"sites/hematologic.md",
"sites/colorectal.md"
] |
46 | codes | Which ICD-10 code is assigned to Colorectal cancer? | [
"C50",
"C18–C21",
"C81–C96",
"C22"
] | 1 | C18–C21 | medium | ICD-10 (C50) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/breast.md",
"sites/colorectal.md",
"sites/hematologic.md",
"sites/liver.md"
] |
47 | codes | Which ICD-10 code is assigned to Hematologic cancer? | [
"C81–C96",
"C22",
"C50",
"C18–C21"
] | 0 | C81–C96 | medium | ICD-10 (C81–C96) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/hematologic.md",
"sites/liver.md",
"sites/breast.md",
"sites/colorectal.md"
] |
48 | codes | Which ICD-10 code is assigned to Liver cancer? | [
"C50",
"C81–C96",
"C22",
"C18–C21"
] | 2 | C22 | medium | ICD-10 (C50) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/breast.md",
"sites/hematologic.md",
"sites/liver.md",
"sites/colorectal.md"
] |
49 | codes | Which ICD-10 code is assigned to Lung cancer? | [
"C81–C96",
"C34",
"C18–C21",
"C50"
] | 1 | C34 | medium | ICD-10 (C81–C96) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/hematologic.md",
"sites/lung.md",
"sites/colorectal.md",
"sites/breast.md"
] |
50 | codes | Which ICD-10 code is assigned to Pancreatic cancer? | [
"C81–C96",
"C50",
"C25",
"C18–C21"
] | 2 | C25 | medium | ICD-10 (C81–C96) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/hematologic.md",
"sites/breast.md",
"sites/pancreatic.md",
"sites/colorectal.md"
] |
51 | codes | Which ICD-10 code is assigned to Prostate cancer? | [
"C61",
"C81–C96",
"C18–C21",
"C50"
] | 0 | C61 | medium | ICD-10 (C61) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/prostate.md",
"sites/hematologic.md",
"sites/colorectal.md",
"sites/breast.md"
] |
52 | codes | Which ICD-10 code is assigned to Melanoma/skin cancer? | [
"C18–C21",
"C50",
"C81–C96",
"C43–C44"
] | 3 | C43–C44 | medium | ICD-10 (C18–C21) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/colorectal.md",
"sites/breast.md",
"sites/hematologic.md",
"sites/skin.md"
] |
53 | codes | Which ICD-10 code is assigned to Carcinoma cancer? | [
"C81–C96",
"C00–C80",
"C18–C21",
"C50"
] | 1 | C00–C80 | medium | ICD-10 (C81–C96) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/hematologic.md",
"sites/colorectal.md",
"sites/breast.md"
] |
54 | codes | Which ICD-10 code is assigned to CNS cancer? | [
"C50",
"C70–C72",
"C18–C21",
"C81–C96"
] | 1 | C70–C72 | medium | ICD-10 (C50) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/breast.md",
"types/cns-cancers.md",
"sites/colorectal.md",
"sites/hematologic.md"
] |
55 | codes | Which ICD-10 code is assigned to Leukemia cancer? | [
"C81–C96",
"C18–C21",
"C91–C95",
"C50"
] | 2 | C91–C95 | medium | ICD-10 (C81–C96) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/hematologic.md",
"sites/colorectal.md",
"types/leukemia.md",
"sites/breast.md"
] |
56 | codes | Which ICD-10 code is assigned to Lymphoma cancer? | [
"C81–C86, C96",
"C18–C21",
"C50",
"C81–C96"
] | 0 | C81–C86, C96 | medium | ICD-10 (C81–C86) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"types/lymphoma.md",
"sites/colorectal.md",
"sites/breast.md",
"sites/hematologic.md"
] |
57 | codes | Which ICD-10 code is assigned to Melanoma cancer? | [
"C18–C21",
"C43",
"C81–C96",
"C50"
] | 1 | C43 | medium | ICD-10 (C18–C21) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/colorectal.md",
"types/melanoma.md",
"sites/hematologic.md",
"sites/breast.md"
] |
58 | codes | Which ICD-10 code is assigned to Myeloma cancer? | [
"C90",
"C81–C96",
"C18–C21",
"C50"
] | 0 | C90 | medium | ICD-10 (C90) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"types/myeloma.md",
"sites/hematologic.md",
"sites/colorectal.md",
"sites/breast.md"
] |
59 | codes | Which ICD-10 code is assigned to Sarcoma cancer? | [
"C18–C21",
"C40–C41, C49",
"C50",
"C81–C96"
] | 1 | C40–C41, C49 | medium | ICD-10 (C18–C21) | https://icd.who.int/browse10/2019/en | [
"types/carcinoma.md",
"know/carcinoma-ref.md"
] | [
"types/carcinoma.md",
"know/carcinoma-ref.md",
"sites/colorectal.md",
"types/sarcoma.md",
"sites/breast.md",
"sites/hematologic.md"
] |
60 | biomarkers | Which biomarker is encoded by the HGNC gene ESR1? | [
"ER (Estrogen Receptor)",
"HER2",
"PR (Progesterone Receptor)",
"Ki67"
] | 0 | ER (Estrogen Receptor) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
61 | biomarkers | Which biomarker is encoded by the HGNC gene PGR? | [
"Ki67",
"HER2",
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)"
] | 2 | PR (Progesterone Receptor) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
62 | biomarkers | Which biomarker is encoded by the HGNC gene ERBB2? | [
"Ki67",
"HER2",
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)"
] | 1 | HER2 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
63 | biomarkers | Which biomarker is encoded by the HGNC gene MKI67? | [
"ER (Estrogen Receptor)",
"HER2",
"Ki67",
"PR (Progesterone Receptor)"
] | 2 | Ki67 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
64 | biomarkers | Which biomarker is encoded by the HGNC gene BRCA1? | [
"HER2",
"ER (Estrogen Receptor)",
"BRCA1",
"PR (Progesterone Receptor)"
] | 2 | BRCA1 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
65 | biomarkers | Which biomarker is encoded by the HGNC gene BRCA2? | [
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)",
"BRCA2",
"HER2"
] | 2 | BRCA2 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
66 | biomarkers | Which biomarker is encoded by the HGNC gene PTEN? | [
"PR (Progesterone Receptor)",
"PTEN (Cowden)",
"ER (Estrogen Receptor)",
"HER2"
] | 1 | PTEN (Cowden) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
67 | biomarkers | Which biomarker is encoded by the HGNC gene PALB2? | [
"HER2",
"ER (Estrogen Receptor)",
"PALB2",
"PR (Progesterone Receptor)"
] | 2 | PALB2 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
68 | biomarkers | Which biomarker is encoded by the HGNC gene CHEK2? | [
"CHEK2",
"HER2",
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)"
] | 0 | CHEK2 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
69 | biomarkers | Which biomarker is encoded by the HGNC gene ATM? | [
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)",
"ATM",
"HER2"
] | 2 | ATM | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
70 | biomarkers | Which biomarker is encoded by the HGNC gene KRAS? | [
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)",
"KRAS",
"HER2"
] | 2 | KRAS | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
71 | biomarkers | Which biomarker is encoded by the HGNC gene EGFR? | [
"EGFR",
"PR (Progesterone Receptor)",
"HER2",
"ER (Estrogen Receptor)"
] | 0 | EGFR | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
72 | biomarkers | Which biomarker is encoded by the HGNC gene ALK? | [
"ER (Estrogen Receptor)",
"HER2",
"PR (Progesterone Receptor)",
"ALK rearrangement"
] | 3 | ALK rearrangement | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
73 | biomarkers | Which biomarker is encoded by the HGNC gene ROS1? | [
"ROS1 rearrangement",
"HER2",
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)"
] | 0 | ROS1 rearrangement | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
74 | biomarkers | Which biomarker is encoded by the HGNC gene BRAF? | [
"PR (Progesterone Receptor)",
"HER2",
"ER (Estrogen Receptor)",
"BRAF V600E"
] | 3 | BRAF V600E | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
75 | biomarkers | Which biomarker is encoded by the HGNC gene MET? | [
"PR (Progesterone Receptor)",
"HER2",
"ER (Estrogen Receptor)",
"MET exon 14 skipping"
] | 3 | MET exon 14 skipping | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
76 | biomarkers | Which biomarker is encoded by the HGNC gene RET? | [
"RET rearrangement",
"HER2",
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)"
] | 0 | RET rearrangement | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
77 | biomarkers | Which biomarker is encoded by the HGNC gene NTRK1? | [
"PR (Progesterone Receptor)",
"NTRK fusion",
"HER2",
"ER (Estrogen Receptor)"
] | 1 | NTRK fusion | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
78 | biomarkers | Which biomarker is encoded by the HGNC gene TP53? | [
"ER (Estrogen Receptor)",
"TP53",
"HER2",
"PR (Progesterone Receptor)"
] | 1 | TP53 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
79 | biomarkers | Which biomarker is encoded by the HGNC gene SMAD4? | [
"SMAD4 (DPC4)",
"PR (Progesterone Receptor)",
"HER2",
"ER (Estrogen Receptor)"
] | 0 | SMAD4 (DPC4) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/30575490 | [
"know/curated.md"
] | [
"know/curated.md"
] |
80 | biomarkers | Which biomarker is encoded by the HGNC gene ARID1A? | [
"ER (Estrogen Receptor)",
"HER2",
"PR (Progesterone Receptor)",
"ARID1A"
] | 3 | ARID1A | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
81 | biomarkers | Which biomarker is encoded by the HGNC gene FOLH1? | [
"HER2",
"ER (Estrogen Receptor)",
"PSMA",
"PR (Progesterone Receptor)"
] | 2 | PSMA | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
82 | biomarkers | Which biomarker is encoded by the HGNC gene AR? | [
"ER (Estrogen Receptor)",
"HER2",
"PR (Progesterone Receptor)",
"AR (Androgen Receptor)"
] | 3 | AR (Androgen Receptor) | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
83 | biomarkers | Which biomarker is encoded by the HGNC gene TMPRSS2-ERG? | [
"TMPRSS2-ERG fusion",
"HER2",
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)"
] | 0 | TMPRSS2-ERG fusion | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"know/curated.md"
] | [
"know/curated.md"
] |
84 | biomarkers | Which biomarker is encoded by the HGNC gene IDH1/IDH2? | [
"PR (Progesterone Receptor)",
"IDH1/IDH2 mutation",
"ER (Estrogen Receptor)",
"HER2"
] | 1 | IDH1/IDH2 mutation | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
85 | biomarkers | Which biomarker is encoded by the HGNC gene TERT? | [
"ER (Estrogen Receptor)",
"TERT promoter mutation",
"HER2",
"PR (Progesterone Receptor)"
] | 1 | TERT promoter mutation | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
86 | biomarkers | Which biomarker is encoded by the HGNC gene ATRX? | [
"HER2",
"ATRX loss",
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)"
] | 1 | ATRX loss | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
87 | biomarkers | Which biomarker is encoded by the HGNC gene NRAS? | [
"HER2",
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)",
"NRAS"
] | 3 | NRAS | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
88 | biomarkers | Which biomarker is encoded by the HGNC gene NF1? | [
"NF1",
"HER2",
"ER (Estrogen Receptor)",
"PR (Progesterone Receptor)"
] | 0 | NF1 | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
89 | biomarkers | Which biomarker is encoded by the HGNC gene KIT? | [
"HER2",
"KIT",
"PR (Progesterone Receptor)",
"ER (Estrogen Receptor)"
] | 1 | KIT | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
90 | biomarkers | With which cancer type is HER2 most closely associated? | [
"Melanoma",
"Breast",
"Colorectal",
"Lung"
] | 1 | Breast | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
91 | biomarkers | With which cancer type is ER (Estrogen Receptor) most closely associated? | [
"Colorectal",
"Breast",
"Lung",
"Melanoma"
] | 1 | Breast | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
92 | biomarkers | With which cancer type is PR (Progesterone Receptor) most closely associated? | [
"Lung",
"Melanoma",
"Breast",
"Colorectal"
] | 2 | Breast | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
93 | biomarkers | With which cancer type is Ki67 most closely associated? | [
"Melanoma",
"Lung",
"Breast",
"Colorectal"
] | 2 | Breast | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/15894097 | [
"know/curated.md"
] | [
"know/curated.md"
] |
94 | biomarkers | With which cancer type is EGFR most closely associated? | [
"Lung",
"Melanoma",
"Colorectal",
"Breast"
] | 0 | Lung | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
95 | biomarkers | With which cancer type is ALK rearrangement most closely associated? | [
"Colorectal",
"Lung",
"Melanoma",
"Breast"
] | 1 | Lung | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
96 | biomarkers | With which cancer type is ROS1 rearrangement most closely associated? | [
"Lung",
"Breast",
"Colorectal",
"Melanoma"
] | 0 | Lung | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
97 | biomarkers | With which cancer type is MET exon 14 skipping most closely associated? | [
"Colorectal",
"Lung",
"Breast",
"Melanoma"
] | 1 | Lung | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
98 | biomarkers | With which cancer type is KRAS most closely associated? | [
"Colorectal",
"Lung",
"Breast",
"Melanoma"
] | 0 | Colorectal | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
99 | biomarkers | With which cancer type is MSI-H / dMMR most closely associated? | [
"Lung",
"Breast",
"Melanoma",
"Colorectal"
] | 3 | Colorectal | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/26244877 | [
"know/curated.md"
] | [
"know/curated.md"
] |
100 | biomarkers | With which cancer type is BRAF V600E most closely associated? | [
"Lung",
"Colorectal",
"Breast",
"Melanoma"
] | 3 | Melanoma | medium | KB-source | https://pubmed.ncbi.nlm.nih.gov/28885881 | [
"know/curated.md"
] | [
"know/curated.md"
] |
Cancer Knowledge Base — the open, verified oncology KB for RAG & LLM evaluation
The only open CC-BY-4.0 oncology knowledge base that combines:
- 110/110 trials cited with PMID + NCT + PubMed/ClinicalTrials.gov URLs, and 32 prognosis rows linked to verified SEER 2016–2022 references — no LLM-synthetic dataset has this.
- A provable 152-question MCQ benchmark — every answer derives from this KB's own structured data and carries a citation + golden docs, so it is open-book verifiable (unlike exam-based medical benchmarks).
- An oncology RAG evaluation suite — 1,239-chunk retrieval pool, 456 MedRGB-style
sufficiency / noise / counterfactual-robustness variants, MIRAGE/MedRGB interchange exports,
a dependency-free harness (
eval_mcq.py), and a submission package. - A ground-truth validation layer that independently audits LLM-synthetic oncology datasets against the KB's cited statements — published scorecards for CancerGUIDE, OncoBench, and MedGUIDE-MCQA-8K.
- Universal TNM / staging + sub-stages (65 staging rows) and ICD-10 / ICD-O-3 / LOINC / HGNC interop codes for joins into precision-oncology pipelines.
- Localization with provenance: 9 locales, 4,728 glossary terms, ≥60% KB-wide translatable coverage for every language, and 20 reviewed-as-auto translation rows.
Educational reference only — not medical advice. Fully de-identified by construction.
Quick start
import pandas as pd
documents = pd.read_parquet("hf://datasets/ranjithraj/cancer-knowledge-base/documents.parquet")
guidelines = pd.read_parquet("hf://datasets/ranjithraj/cancer-knowledge-base/guidelines.parquet")
trials = pd.read_parquet("hf://datasets/ranjithraj/cancer-knowledge-base/evidence_levels.parquet")
# Full-text search any document (FTS is a first-class column)
breast = documents[documents.path == "know/breast-ref.md"].body.iloc[0]
# Every guideline statement, citation-linked
print(guidelines[guidelines.source == "know/breast-ref.md"])
# 152 provable MCQs with difficulty / evidence / citation / golden docs
mcq = pd.read_parquet("hf://datasets/ranjithraj/cancer-knowledge-base/mcq_questions.parquet")
Evaluate your own RAG/LLM on the oncology benchmark in one command:
python3 scripts/eval_mcq.py --retriever bm25 --topk 3 # BM25 end-to-end
python3 scripts/eval_mcq.py --predictions preds.jsonl # score your system
A 3-minute Colab walkthrough is at colab_quickstart.ipynb — load the KB,
run BM25 retrieval, and reproduce the benchmark baseline.
Suggested uses
- RAG evaluation — score your retriever+generator on
benchmark/(MIRAGE/MedRGB interchangeable). - Fine-tuning — instruction-tune or domain-adapt small LLMs for oncology QA on the 58 de-identified documents.
- Benchmarking synthetic data — screen LLM-generated oncology datasets against the KB's evidence index (
scripts/validate_synthetic.py). - Multilingual oncology content — build localized Q&A or terminology tools from the code-anchored glossary (9 locales).
- Entity linking / coding — ICD-10 / LOINC / ICD-O-3 / HGNC mappings in
codes.parquet.
Citation
@misc{cancer-knowledge-base-2026,
title = {{Cancer Knowledge Base}: an open, verified, provable oncology knowledge base for RAG and LLM evaluation},
author = {Ranjithraj, {R}},
year = {2026},
howpublished = {\url{https://huggingface.co/datasets/ranjithraj/cancer-knowledge-base}},
note = {CC-BY-4.0; 110/110 trials cited; 152-question provable MCQ benchmark; validation scorecards for CancerGUIDE/OncoBench/MedGUIDE}
}
Contents (parquet files)
| File | Rows | Description |
|---|---|---|
documents.parquet |
58 | De-identified documents: metadata + body text |
sections.parquet |
402 | Markdown headings + verbatim section content |
markdown_tables.parquet |
212 | All markdown tables (header/rows as JSON) |
markdown_links.parquet |
154 | Internal links between documents |
prognosis.parquet |
168 | Lethality/survival tables by cancer type and stage (dated, educational) |
biomarkers.parquet |
72 | Mutations, receptors, genetic syndromes |
guidelines.parquet |
175 | Guideline-grade treatment statements per cancer (NCCN/ESMO/ASCO) |
subtypes.parquet |
110 | Histologic subtypes by cancer |
drugs.parquet |
102 | Drugs, class, mechanism, toxicity |
staging.parquet |
65 | Staging systems + universal TNM/Stage 0-IV + sub-stages |
regimens.parquet |
85 | Treatment regimens per case and phase |
monitoring.parquet |
109 | Factors to monitor during chemo/targeted/surgery/RT |
diagnostics.parquet |
96 | Recommended diagnostics per case |
labs.parquet |
72 | Baseline labs (synthetic, clearly flagged) |
imaging_findings.parquet |
59 | PET-CT / imaging findings (synthetic, clearly flagged) |
consultations.parquet |
59 | Consultation plan evolution (synthetic, clearly flagged) |
case_facts.parquet |
218 | Structured case fields (diagnosis, staging, prognosis) |
evidence_levels.parquet |
115 | Evidence grading (guidelines + trials) per entity — 110 trials with PMID/NCT/URL |
codes.parquet |
82 | Interop codes: ICD-10 sites/types, HGNC biomarkers, LOINC labs, ICD-O-3 breast subtypes |
regimen_drugs.parquet |
100 | Regimen-to-drug join table |
mcq_questions.parquet |
152 | 152 provable oncology MCQs with difficulty / evidence / citation / golden docs |
prognosis_sources.parquet |
32 | Prognosis rows linked to verified SEER references (vintage + value) |
locales.parquet |
9 | Registered target languages (BCP-47 codes, review requirement, priority) |
glossary.parquet |
4728 | Code-anchored terminology registry: concept -> code (ICD/LOINC/HGNC/ICD-O-3) -> local term per locale |
translations.parquet |
20 | Per-document localized bodies with master_hash/content_hash provenance and review status |
RAG Benchmark
benchmark/ contains an oncology RAG evaluation suite built from this knowledge base:
retrieval_pool.parquet— 1,239 chunked retrieval units (sections, markdown tables, domain tables)mcq_benchmark.parquet— 152 multiple-choice questions with golden docs, difficulty, evidence level, and citationsmcq_robustness.parquet— 456 MedRGB-style variants (sufficiency / noise / counterfactual-robustness)mirage_format.jsonl/medrgb_format.jsonl— interchange exports for MIRAGE-family leaderboards and MedRGB harnesses (seebenchmark/MIRAGE_INTEGRATION.md)leaderboard.json+releases/*.json— recorded results with KB-commit / date / release snapshots for growth trackingbaseline_preds.jsonl+SUBMISSION.md— reproducible baseline and submission protocol
Baseline (BM25@top3, no LLM): sufficiency 31.6% (random = 25%), retrieval@3 61.8%. Real headroom for embedding retrievers and strong generators — the pool is provably answerable, so gains are attributable to retrieval + reasoning, not answer leakage.
Ground-truth validation scorecards
scorecards/ holds the results of screening LLM-synthetic oncology datasets against the KB's cited
statements (scripts/validate_synthetic.py). Each claim is tiered supported / partial / unsupported
by lexical coverage of site-gated evidence, and every item links to the matching evidence chunk.
cancerguide.all.summary.md— CancerGUIDE (316 synthetic patient notes): 238 scorable claims, 87.0% supported / 12.6% partial / 0.4% unsupported.oncobench.all.summary.md— OncoBench strong100 (100 adjudicated decision cases): 2,007 claims, 26.0% supported — the scorecard doubles as a KB coverage-gap map.medguide.all.summary.md— MedGUIDE-MCQA-8K (7,747 NCCN decision-tree MCQs): 6,952 claims, 21.2% supported.
Localization (l10n)
The KB is localized with provenance — every translation keeps its citation (via the master
document), a master_hash so a change in the English source flags the locale stale, and an explicit
review status (auto → reviewed → approved). All 9 registered locales are at ≥60% KB-wide
translatable coverage (de/es/hi/zh ~520-525 terms, ar/bn/pt-BR/sw/te 527 terms each; 4,728
glossary terms total), measured script-agnostically across all 58 documents.
locales.parquet— registered languages (de, zh, es, hi, ar, bn, pt-BR, sw, te)glossary.parquet— code-anchored terminology registry: each concept is linked to its language-neutral code (ICD-10 / ICD-O-3 / LOINC / HGNC) and maps to the local clinical term, so structured rows localize for free while codes stay the join key across languages.translations.parquet— localized document bodies (5 reference docs at 100% translatable coverage in de/zh/es/hi) withmaster_hash/content_hashandstatus.l10n/*/mcq.*.jsonl— localized MCQ exports (de/es/hi/zh) with preserved answer indices.
Coverage is not clinical approval: status='auto' rows are glossary-generated drafts that must
be clinically reviewed (reviewed) before use. See l10n-moat.md and
scripts/localize_pilot.py --coverage.
Privacy
This is the de-identified public subset. The real patient case (cases/specific/ — PHI) and all
content derived from it are excluded. Documents are filtered by phi = 0.
Synthetic rows in labs, imaging_findings, and consultations are clearly flagged with
synthetic = 1 and are illustrative public-case data — they are not real patient values.
Disclaimer
Educational reference only — not medical advice. Survival figures are population averages and may
be outdated (prognosis.as_of marks their review date); consult current guidelines and clinicians for
patient decisions.
- Downloads last month
- 135